Skip to content
Study details
Enrolling now

A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

Nested Therapeutics, Inc
NCT IDNCT06326411ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

230

Study length

about 5.6 years

Ages

18+

Locations

17 sites in CA, CO, CT +7

What this study is about

Researchers are testing a treatment called NST-628 for adults with solid tumors that have not responded to other treatments. The trial will evaluate how safe and effective this treatment is.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take NST-628

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Standard assignment

Assignment is predetermined by the study protocol.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Part B: Evaluate objective tumor response rate

Secondary: Part A and B: Characterize the pharmacokinetics of NST-628, Part A and B: Evaluate overall survival (OS), Part A and B: Evaluate progression free survival (PFS), Part A: Evaluate objective tumor response rate

Body systems

Oncology